GILD
Gilead Sciences
$124.87
▲ 0.9%Updated Today 6:01 PM ET
▲ Up 14.6% over the last 12 months
Market Cap
$153.66B
P/E
16.57x
Forward P/E (est.)
11.84x
ROE
42.2%
Revenue Growth
3.5%
EPS Growth
55.5%
Profit Margin
31.0%
FCF Yield
5.2%
Debt / Equity
1.1x
ROIC
17.0%
Interest Coverage
10.62x
Current Ratio
1.97x
Dividend Yield
2.6%
Implied Growth (rev. DCF)
2.7%
Rating Score
74/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what GILD's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. GILD trades near $124.87, below its 50-day average ($131.78) and 200-day average ($129.40). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 31 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. GILD's is $3.78 (~3.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month GILD found buyers near $121.39 (support) and sellers near $137.20 (resistance); its 52-week range is $104.46–$157.29. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.6× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Gilead Sciences (GILD) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $153.66B.
In its latest reported year it generated about $29.44B in revenue and $8.51B in net profit.
Our model rates GILD Strong (74/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
1.9%
Revenue moved from $27.30B in 2021 to $29.44B in 2025, a 1.9% compound annual growth rate. The most recent year was roughly flat (3.5%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
79.3%
Operating Margin
34.0%
Net Margin
28.9%
ROE
42.2%
Gilead Sciences keeps about 31.0% of each sales dollar as net profit, with a 79.3% gross margin and 34.0% operating margin. Return on equity is 42.2% and return on invested capital about 17.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$22.17B
Net Debt
$16.76B
Net Debt / EBITDA
1.67x
Debt / Equity
1.1x
Leverage: debt-to-equity is 1.1x, and operating profit covers interest about 10.6x, with a current ratio of 2.0x. That is a moderate, manageable debt load for most businesses. It carries roughly $22.17B of total debt against $5.41B of cash.
Operating CF
$10.02B
Free Cash Flow
$9.46B
FCF Margin
32.1%
In the latest year Gilead Sciences produced about $10.02B of operating cash flow and $9.46B of free cash flow after capital spending. That is a free-cash-flow yield of about 5.2% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
16.57x
P/S
5.33x
P/B
6.52x
EV / EBITDA
—
GILD trades at 16.6x trailing earnings (about 11.8x on estimated forward earnings), 5.3x sales, and 6.5x book value. Reverse-engineering today's price implies the market expects roughly 2.7% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How GILD stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), GILD ranks #3 of 59 by our overall rating. It trades at a discount versus the sector on earnings (16.6x P/E vs. 25.4x median) with a higher return on equity (42.2% vs. 14.9%) and slower revenue growth (3.5% vs. 7.9%).
P/E vs sector
16.6x
median 25.4x
ROE vs sector
42.2%
median 14.9%
Growth vs sector
3.5%
median 7.9%
Sector rank
#3
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$79.73 – $135.53
vs. $124.87 today · expected CAGR -9% – 2%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $30.33B | $31.24B | $32.17B | $33.14B | $34.13B |
| Net income | $8.79B | $9.06B | $9.33B | $9.61B | $9.90B |
| EPS | $7.08 | $7.30 | $7.51 | $7.74 | $7.97 |
| Share price (low) | $70.83 | $72.96 | $75.15 | $77.40 | $79.73 |
| Share price (high) | $120.42 | $124.03 | $127.75 | $131.59 | $135.53 |
| CAGR (low–high) | -43% / -4% | -24% / -0% | -16% / 1% | -11% / 1% | -9% / 2% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for GILD:
- High net margins (31.0%) point to pricing power or efficiency.
- Strong return on equity (42.2%) shows capital is put to work well.
- Healthy free-cash-flow yield (~5.2%) funds buybacks and dividends.
- Pays a 2.6% dividend on top of any price gains.
- Our model's overall read is Strong (74/100).
The case against GILD:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 1.1x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Gilead Sciences is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 16.6x earnings, which our model scores Strong (74/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.